- Company
- “30-year presence of antihypertensive Novarsc to continue"
- by Eo, Yun-Ho Dec 22, 2020 06:13am
- Norvasc (amlodipine) is not the world’s first calcium channel blocker (CCB). However, it is undisputedly the most famous CCB. Launched in 1990s, Norvasc was not the first-in-class but it instigated a notable change in the market with the first once-daily administration. Some say the drug marked the early beginning of the current day co
- Company
- Boryung's FAH is expected to be released soon
- by Kim, Jin-Gu Dec 22, 2020 06:10am
- Boryung's hypertension combination drug is expected to be released in the second half of next year. If FAH is released next year as planned by Boryung, it will be the 7th 'Kanarb Family'. Interest is focused on whether to continue the Ducaro and Archave successes as the 5th and 6th Kanarb family this year. According to the pharmaceut
- Company
- First line therapy for NSNLC, starts of combination therapy
- by Eo, Yun-Ho Dec 22, 2020 06:09am
- Various combinations have been approved for NSNLC (non-small cell lung cancer), the most competitive field for new anticancer drugs. Competition is expected to intensify in the future as numerous studies are underway based on immuno-cancer drugs and targeted anti-cancer drugs. Lilly threw the hat into the ring in Korea. The company is
- Company
- CKD to outrun SK and Hanmi with Xarelto patent challenge
- by Kim, Jin-Gu Dec 22, 2020 06:09am
- Chong Kun Dang is now the sole contender to challenge Bayer’s non-Vitamin K antagonist oral anticoagulants (NOAC) Xarelto (rivaroxaban) substance patent. As it overcame Xarelto’s formulation patent, Chong Kun Dang plans to enter the follow-on drug market faster than SK Chemicals and Hanmi Pharmaceutical, who won the preferential sales
- Company
- Another effect of Botox, possible to treat hair loss
- by Dec 21, 2020 06:19am
- Following cosmetic surgery, botulinum toxin formulations are expanding their scope to treat hair loss. It is noteworthy as researches confirming the potential as a treatment for hair loss in Korea are ongoing. Dankook University dermatology professor Park Byeong-cheol confirmed the effect of botulinum toxin on hair loss improvement in the
- Company
- US ITC bans Nabota from importing for 21 months
- by An, Kyung-Jin Dec 21, 2020 06:19am
- The US International Trade Commission (ITC) issued an order to ban imports from the US for 21 months on Jubo (Nabota), a botulinum toxin product developed by Daewoong. According to industry sources on the 17th, the US ITC issued a final ruling on the 16th (local time) in a lawsuit between Medy Tox and Daewoong infringement of trade secret
- Company
- Orally taken Rinvoq to be prescribed in general hospitals
- by Eo, Yun-Ho Dec 18, 2020 06:07am
- A third Janus kinase (JAK) inhibitor in South Korea, Rinvoq is swiftly seeking for prescription authorization in general hospitals nationwide immediately after it was listed for the healthcare reimbursement. An industry source reported AbbVie’s Rinvoq (upadacitinib) has been recently passed by the drug committees (DCs) at Seoul Asan Med
- Company
- When will K-COVID-19 vaccine be released?
- by Kim, Jin-Gu Dec 18, 2020 06:06am
- As Pfizer's COVID-19 vaccination has begun one after another in the UK and the US, interest in domestic companies that have jumped into COVID-19 vaccine development is also increasing. Currently, it is predicted that the commercialization of vaccines developed by domestic companies will be possible only in 2023 even if the commercializatio
- Company
- Drug export breaks record making near KRW 7 trillion
- by Kim, Jin-Gu Dec 18, 2020 06:05am
- The South Korean-made pharmaceutical export broke the record this year. The accumulated export volume up to November has already exceeded the total export volume in last year. Due to a steep surge in pharmaceutical export, the industry trade performance is expected to hit the highest point in the history. According to the Korea Customs Servi
- Company
- Who distributes Pfizer-Moderna vaccine in South Korea?
- by Kim, Jin-Gu Dec 17, 2020 06:12am
- Just as Pfizer has, Moderna is getting close to receive the U.S. Food and Drug Administration’s (FDA) emergency use authorization for its COVID-19 vaccine. Currently, the South Korean government is in negotiation with two companies to supply their vaccines in the country. The attention is focused on how the vaccines would be manufacture
